KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 268.63%.

  • Nektar Therapeutics' EBIT Margin fell 1262700.0% to 268.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.69%, marking a year-over-year increase of 76400.0%. This contributed to the annual value of 106.88% for FY2024, which is 1857100.0% up from last year.
  • Per Nektar Therapeutics' latest filing, its EBIT Margin stood at 268.63% for Q3 2025, which was down 1262700.0% from 324.21% recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' EBIT Margin peaked at 49.18% during Q4 2024, and registered a low of 708.07% during Q2 2022.
  • For the 5-year period, Nektar Therapeutics' EBIT Margin averaged around 320.47%, with its median value being 268.63% (2025).
  • As far as peak fluctuations go, Nektar Therapeutics' EBIT Margin plummeted by -3190600bps in 2022, and later soared by 4612300bps in 2023.
  • Over the past 5 years, Nektar Therapeutics' EBIT Margin (Quarter) stood at 451.48% in 2021, then surged by 47bps to 238.25% in 2022, then skyrocketed by 41bps to 140.3% in 2023, then soared by 135bps to 49.18% in 2024, then crashed by -646bps to 268.63% in 2025.
  • Its EBIT Margin stands at 268.63% for Q3 2025, versus 324.21% for Q2 2025 and 425.76% for Q1 2025.